High-dose deferoxamine treatment (intravenous) for thalassaemia patients with cardiac complications.
As a means to manage cardiac conditions, we determined the effects of high-dose intravenous (IV) deferoxamine in 15 thalassaemia patients with cardiomyopathy and high ferritin and haemoglobin levels. The patients received IV deferoxamine, 130 mg/kg per day over 10-14 hours (maximum 5 g) for 5 consecutive days. All patients underwent a full evaluation before receiving deferoxamine, and 2 days and 1 month after completing the treatment. Visual and auditory examinations were done to detect any side-effects. After treatment, cardiovascular symptoms decreased considerably and systolic function showed significant improvement, but there was no significant effect on diastolic function, electrocardiography and physical findings. There were no significant side-effects reported.
Ghader
F R
FR
Booali Hospital, Sari, Islamic Republic of Iran. fashid83@yahoo.com
Kousarian
M
M
Farzin
D
D
D000293:Adolescent; D000328:Adult; D009202:Cardiomyopathies / Q000097:blood / Q000209:etiology* / Q000503:physiopathology; D015913:Chelation Therapy / Q000009:adverse effects / Q000379:methods; D003676:Deferoxamine / Q000008:administration & dosage* / Q000494:pharmacology; D003971:Diastole / Q000187:drug effects; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D005293:Ferritins / Q000187:drug effects / Q000378:metabolism; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D006486:Hemosiderosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D012449:Safety; D017262:Siderophores / Q000008:administration & dosage* / Q000494:pharmacology; D013599:Systole / Q000187:drug effects; D065227:Transfusion Reaction; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects; D017086:beta-Thalassemia / Q000150:complications / Q000628:therapy*
D006454:Hemoglobins; D017262:Siderophores; D005293:Ferritins; D003676:Deferoxamine